🔗 Share this article

As the United States proceeds with sweeping revisions to its vaccination guidelines, a particular individual appears in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning COVID-19 vaccines during the pandemic and has focused upon alleged deaths after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Schedule

Agency leaders were set to announce sweeping changes to the pediatric immunization program earlier this month, bringing the US with Denmark’s national calendar, sources say – a substantial departure that would put the US out of step with much of the world with no evidence for improved outcomes. The announcement has been postponed until the coming year.

In place of the top vaccines chief, Dr. Høeg is listed to speak at the event. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to head the office this year.

A New Direction at the Agency

This interim role may indicate a closer partnership between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a greater focus upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric immunization guidelines in the US in order to be more similar to Denmark, a country with comprehensive healthcare and a population about the size of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – typically the responsibility of Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Qualifications

Høeg has no apparent experience in drug development, approval processes or leadership, which has been customary for previous leaders of the CBER. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in managing a major agency. She is not an expert in drug approvals.”

Former directors of the center would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she lacks the kind of background that prior appointees who led the center have had.”

CDER has an immense range of responsibilities at the agency, the former commissioner pointed out.

“The public just zeroes in on the novel medication approvals, but the generic drug division clears thousands of generic medications. There is also a biosimilars program, over-the-counter program and so forth, and every single one must be supervised,” she explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial leadership element to the job, which manages over 5,000 personnel. “It’s a massive leadership role, if you do it right,” she said.

Official Statement and Controversial Programs

Regarding concerns about Dr. Høeg's qualifications and whether this appointment represents increased cooperation among regulatory chiefs on immunizations, a press secretary said that the “concerns rely on flawed presumptions”.

“Her resume aligns with the functions of her position,” the official stated, noting the period Høeg spent advising the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a disputed expedited therapy clearance system that apparently concerned her predecessors. “How are these therapies being selected for this fast-track system? Who makes the choices?” Dr. Howard asked. “There’s a lot of lack of transparency happening at the agency right now.”

Overall, he remarked, “the agency looks to be trending towards less stringent oversight of pharmaceuticals, aside from immunizations.”

Documented History on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if concerning, track record, some experts observe. She published a study using non-validated crowd-sourced reports to determine the frequency of heart inflammation after COVID-19 vaccination. She counseled the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the incoming administration encompassed altering regulations for novel immunizations and ending “unnecessary” vaccines, she stated following the vote on a podcast. At the FDA, Dr. Høeg has reportedly proposed excluding young men from obtaining COVID-19 vaccines.

“She is an complete true believer who starts off with her beliefs and works backwards to fit the evidence in a very deceptive, fraudulent way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with fellow dissenters, {like|